Biomerica vs ImmuCell
BMRA and ICCC side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How BMRA and ICCC compare
ImmuCell is the larger company, worth 17 times as much as Biomerica ($104M against $6.1M).
ImmuCell grew revenue faster over the last twelve months (8.5% versus −11.2% for Biomerica).
ImmuCell keeps more of each dollar of sales as profit, with a net margin of 2.6% compared with −115% at Biomerica.
ImmuCell scores higher on the StockData Score (13 against 8 for Biomerica), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | BMRA | ICCC |
|---|---|---|
| Size and price | ||
| Market cap | $6.1M | $104M |
| Share price | $1.32 | $11.42 |
| Change, 1 year | −47.2% | 88.8% |
| Change, 5 years | −96.7% | 24.1% |
| Beta (5Y) | 0.84 | 0.73 |
| Employees | 17 | 73 |
| StockData Score | ||
| Total score | 8 | 13 (better) |
| Valuation score | 3 (better) | 1 |
| Growth score | 0 | 3 (better) |
| Performance score | 0 | 4 (better) |
| Health score | 5 | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | – | 143× |
| P/S | 1.4× (better) | 3.4× |
| P/B | 1.7× (better) | 3.3× |
| EV/EBITDA | – | 16.4× |
| P/FCF | – | 24.6× |
| FCF yield | – | 4.1% |
| Fair value | $2.49 | $11.04 |
| Margin of safety | 47.0% (better) | −3.4% |
| Growth | ||
| Revenue growth (TTM) | −11.2% | 8.5% (better) |
| Revenue growth, 5Y average | −9.2% | 12.5% (better) |
| Net income growth (TTM) | – | −55.3% |
| EPS growth (TTM) | – | −57.9% |
| Profitability | ||
| Gross margin | 0.90% | 40.3% (better) |
| Operating margin | −125% | 12.6% (better) |
| Net margin | −115% | 2.6% (better) |
| FCF margin | – | 13.7% |
| Return on equity | −114% | 2.6% (better) |
| Return on invested capital | −284% | 11.1% (better) |
| Financial health | ||
| Debt / equity | 0.00 | 0.26 (better) |
| Net debt / EBITDA | – | −0.09 |
| Interest coverage | – | 8.9× |
| Current ratio | 1.91 | 4.75 (better) |
| Altman Z-score | −10.57 | 5.10 (better) |
| Piotroski F-score | 4 | 7 (better) |
| Dividends and buybacks | ||
| Buyback yield | −52.2% | 0.00% (better) |
| Shareholder yield | −52.2% | 0.00% (better) |
| Ownership | ||
| Held by institutions | 2.7% | 14.7% |
| Held by insiders | 27.4% | 13.6% |
| Insider net buying, 12 months | $158K (better) | $156K |
| Short interest, % of float | 0.37% | 0.19% |
Go deeper
- BMRA stock overview
- BMRA income statement
- BMRA valuation and score
- ICCC stock overview
- ICCC income statement
- ICCC valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.